
    
      A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild
      to moderate allergic asthma not sufficiently controlled on inhaled steroid.

      Altogether 170 patients, randomized to two treatment groups will be included. Key outcome
      measures are patient reported parameters on their asthma at the time of primary endpoint and
      throughout the study.
    
  